Santen today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children.[3] The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow.[4,5]Read More
Santen Receives UK Approval for Ryjunea® (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia
By PR Newswire
